MAGROLIMAB

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Investigational

Investigational

Approval Year

Substance Class	Protein Created by `admin` on `Mon Mar 31 22:34:27 GMT 2025` Edited by `admin` on `Mon Mar 31 22:34:27 GMT 2025`
Protein Type	MONOCLONAL ANTIBODY
Protein Sub Type	IGG4
Sequence Origin	HUMANIZED MOUSE
Sequence Type	COMPLETE
Record UNII	90YIEHRFJ9
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MAGROLIMAB

Official Name

English

HU5F9-G4

Preferred Name

English

Magrolimab [WHO-DD]

Common Name

English

ANTI-CD47 MONOCLONAL ANTIBODY HU5F9-G4

Common Name

English

IMMUNOGLOBULIN G4-KAPPA, ANTI-(HOMO SAPIENS CD47 (INTEGRIN ASSOCIATED PROTEIN, IAP, MER6, OA3)), MONOCLONAL ANTIBODYGAMMA4 HEAVY CHAIN (1-444) (VH (HOMO SAPIENS IGHV1-3*01 (87.8%)-(IGHD)-IGHJ4*01 (100%)) (8.8.10) (1-117)-HOMO SAPIENS IGHG4*01 (CH1 (118-2

Systematic Name

English

MAGROLIMAB [USAN]

Common Name

English

magrolimab [INN]

Common Name

English

IMMUNOGLOBULIN G4(225-PROLINE), ANTI-(HUMAN CD47 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL HU5F9-G4 .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL HU5F9-G4 .KAPPA.-CHAIN, DIMER

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C129822

Created by admin on Mon Mar 31 22:34:27 GMT 2025 , Edited by admin on Mon Mar 31 22:34:27 GMT 2025

FDA ORPHAN DRUG

488515

Created by admin on Mon Mar 31 22:34:27 GMT 2025 , Edited by admin on Mon Mar 31 22:34:27 GMT 2025

NCI_THESAURUS

C20401

Created by admin on Mon Mar 31 22:34:27 GMT 2025 , Edited by admin on Mon Mar 31 22:34:27 GMT 2025

FDA ORPHAN DRUG

716319

Created by admin on Mon Mar 31 22:34:27 GMT 2025 , Edited by admin on Mon Mar 31 22:34:27 GMT 2025

Code System Code Type Description

INN

10999

Created by admin on Mon Mar 31 22:34:27 GMT 2025 , Edited by admin on Mon Mar 31 22:34:27 GMT 2025

PRIMARY

FDA UNII

90YIEHRFJ9

Created by admin on Mon Mar 31 22:34:27 GMT 2025 , Edited by admin on Mon Mar 31 22:34:27 GMT 2025

PRIMARY

CAS

2169232-81-7

Created by admin on Mon Mar 31 22:34:27 GMT 2025 , Edited by admin on Mon Mar 31 22:34:27 GMT 2025

PRIMARY

USAN

HI-132

Created by admin on Mon Mar 31 22:34:27 GMT 2025 , Edited by admin on Mon Mar 31 22:34:27 GMT 2025

PRIMARY

NCI_THESAURUS

C117730

Created by admin on Mon Mar 31 22:34:27 GMT 2025 , Edited by admin on Mon Mar 31 22:34:27 GMT 2025

PRIMARY

SMS_ID

100000180080

Created by admin on Mon Mar 31 22:34:27 GMT 2025 , Edited by admin on Mon Mar 31 22:34:27 GMT 2025

PRIMARY

From	To
1_22	1_96
2_22	2_96
1_144	1_200
2_144	2_200
1_258	1_318
2_258	2_318
1_364	1_422
2_364	2_422
3_23	3_93
4_23	4_93
3_139	3_199
4_139	4_199
1_223	2_223
1_226	2_226
1_131	3_219
2_131	4_219

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_294
N	2_294

Related Record Type Details


					90DHW5TM9S

LEUKOCYTE SURFACE ANTIGEN CD47

TARGET -> INHIBITOR

Comments:

prevents CD47/SIRPa-mediated signaling, allows the activation of macrophages, through the induction of pro-phagocytic signaling mediated by calreticulin, which is specifically expressed on the surface of tumor cells, and results in specific tumor cell phagocytosis. In addition, blocking CD47 signaling activates an anti-tumor T-lymphocyte immune response and T-mediated cell killing. CD47, a tumor associated antigen expressed on normal, healthy hematopoietic stem cells (HSC), is overexpressed on the surface of a variety of cancer cells. Expression of CD47, and interaction with SIRP-alpha, leads to inhibition of macrophages and protects cancer cells from phagocytosis thereby allowing cancer cells to proliferate.

Related Record Type Details


					90YIEHRFJ9

ACTIVE MOIETY

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL
Molecular Formula	CHEMICAL